Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study
| Autor: | Nicolas Magné, Jean-Phillipe Jacquin, Pauline Doucey, Elise Rowinski, Benoîte Méry, Xavier Simoens, Alexis Vallard |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Vascular Endothelial Growth Factor A
Oncology Cancer Research medicine.medical_specialty Biomedical Research Paclitaxel Bevacizumab Receptor ErbB-2 Cost-Benefit Analysis Triple Negative Breast Neoplasms Medical Oncology 03 medical and health sciences 0302 clinical medicine Breast cancer Maintenance therapy Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans 030212 general & internal medicine Neoplasm Metastasis Triple-negative breast cancer Aged business.industry Cancer Retrospective cohort study General Medicine Middle Aged medicine.disease Metastatic breast cancer Progression-Free Survival 030220 oncology & carcinogenesis Female business Cohort study medicine.drug |
| Zdroj: | Oncology. 97:1-6 |
| ISSN: | 1423-0232 0030-2414 |
| DOI: | 10.1159/000499583 |
| Popis: | Background: Triple-negative breast cancer remains a disease with poor prognosis and few treatment options, due to the lack of therapeutic targets. Bevacizumab, the first anti-VEGF agent approved in the treatment of cancer, has demonstrated efficacy in breast cancer in combination with paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer. Despite the fact that the benefit was particularly significant for triple-negative breast cancer with its approval in 2008 by the FDA, this decision was later reversed as there was no improvement in overall survival in addition to significant costs. Objectives: The scope of the present study is to focus on the role of bevacizumab in triple-negative breast cancer through the analysis of overall survival, progression-free survival, and cost benefit among 45 patients in a French monocentric study and to discuss new paradigms of endpoints. Methods: All patients diagnosed with metastatic triple-negative breast cancer, for whom first-line treatment was bevacizumab in combination with paclitaxel between January 2011 and April 2018 were included in this single-center retrospective study, and a chart review of all recruited subjects was performed from medical records. Results: In this real-life study among 45 patients with metastatic triple-negative breast cancer, bevacizumab provided a significant benefit for a category of patients, with longer median progression-free survival and the ability of maintenance therapy associated to limited side effects. Conclusions: Beyond being the phoenix of breast oncology and a magnet of controversy, the case of bevacizumab in metastatic breast cancer highlights one of the greatest challenges in oncology, namely to balance modest clinical benefits with exponential costs. A balance needs to be found between health care affordability, high price of progress, and the best medical decision for the patients, in order to avoid the “unbreathable tipping point” we are actually dealing with. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|